| 周宁 李娜 马兰英 许春蕾 唐勇.FOLFOX方案治疗胃癌的疗效及对血清INF-r和IL-4 水平的影响[J].,2015,15(12):2316-2318 |
| FOLFOX方案治疗胃癌的疗效及对血清INF-r和IL-4 水平的影响 |
| Efficacy of FOLFOX Regimen for Patients with Gastric Cancer and Its Effecton Levels of SerumINF-r and IL-4 |
| |
| DOI： |
| 中文关键词: 胃癌 FOLFOX 方案 INF-γ IL-4 |
| 英文关键词: Gastric cancer FOLFOX regimen INF-γ IL-4 |
| 基金项目: |
|
| 摘要点击次数: 646 |
| 全文下载次数: 593 |
| 中文摘要: |
| 目的：探讨FOLFOX方案治疗胃癌的疗效及对血清干扰素-γ(INF-γ)和白细胞介素-4(IL-4)水平的影响。方法：选择我院2011
年1 月至2014 年1 月收治的胃癌患者80 例，按随机数字表法平均分为两组，研究组及对照组各40 例，以3 周为1 个疗程,治疗
3 个疗程。研究组患者给予FOLFOX方案治疗，对照组患者给予ELF化疗方案，3 个疗程后，比较两组患者治疗有效率，同时比较
两组患者治疗前后血清INF-γ和IL-4 水平变化及不良反应发生情况。结果：3 个疗程后，研究组患者治疗有效率为57.5%，明显高
于对照组37.5%，比较差异具有统计学意义（P＜0.05）。两组患者治疗后血清INF-γ水平及INF-γ/ IL-4 值较治疗前明显升高，而
IL-4 水平较治疗前明显下降，且研究组患者两种细胞因子水平改善程度均明显优于对照组，比较差异具有统计学意义（P＜0.05）。
研究组患者白细胞减少、血小板下降及恶心呕吐不良反应发生率分别为22.5%、7.5%及27.5%，与对照组25.0%、10.0%及32.5%，
比较差异无统计学意义（P＞0.05）。结论：FOLFOX方案治疗胃癌效果显著，可有效改善患者机体免疫水平，提高抗肿瘤效果，值得
临床推广应用。 |
| 英文摘要: |
| Objective:To investigate the curative effect of FOLFOX regimen in treatment of patients with gastric cancer and its
effect on levels of serum interferon gamma (INF-γ) and interleukin -4(IL-4).Methods:A total of 80 patients with gastric cancer, admitted
to the Affiliated Tumor Hospital of Xinjiang Medical University from January 2011 to January 2014, were randomly divided into study
group(n=40) and control group(n=40). The study group was treated with FOLFOX regimen for 9 weeks(3 weeks was a course ); while the
control group was treated with ELF chemotherapy for 9 weeks. After 3 courses of treatment, the effective rates, levels of serum INF-γ
and IL-4 before and after treatment, and incidence of adverse reactions of the two groups were compared.Results:After 3 courses of
treatment, the effective rate (57.5%) of the study group was significantly higher than that (37.5%) of the control group, with significant
difference (P<0.05). Compared with before therapy, serum INF-γ and INF-γ/ IL-4 values of the two groups were significantly increased
after treatment, but level of IL-4 decreased, and improvement of the two kinds of cytokines levels in the study group was significantly
better than that of the control group, with significant difference (P<0.05). The adverse reaction rate of leukopenia, thrombocytopenia and
nausea/vomiting of the study group was 22.5%, 7.5% and 27.5%respectively; of the control group, 25%,10.0% and 32.5%respectively.
There was no significant difference between the two groups (P>0.05).Conclusion:FOLFOX regimen has a significant effect in the
treatment of patients with gastric cancer,which can effectively improve the immune level of the body , enhance the anti-tumor effect and
is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
